In vivo regulation of neurotensin receptors following long-term pharmacological blockade with a specific receptor antagonist

Molecular Brain Research

Volumn 42, Issue 2, 1996, Pages 213-221

  Azzi, Mounia ^a   Boudin, Hélène ^a   Mahmudi, Nasire ^a   Pélaprat, Didier ^a   Rostène, William ^a   Bérod, Anne ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

G protein coupled receptor; Gene regulation; Hybridization, in situ; Rat brain; Receptor antibody; SR 48692

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; MESSENGER RNA; NEUROTENSIN RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIENCEPHALON; GENE CONTROL; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SUPRACHIASMATIC NUCLEUS; VENTRAL TEGMENTUM;

ANIMALS; BRAIN; IN SITU HYBRIDIZATION; MALE; PROTEINS; PYRAZOLES; QUINOLINES; RATS; RATS, WISTAR; RECEPTORS, NEUROTENSIN; TIME FACTORS;

ANIMALIA;

EID: 0030472839     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(96)00124-6     Document Type: Article

References (59)

1. [1] Alexander, M.J., Mahoney, P., Ferris, C., Carraway, R.E. and Leeman, S.E., Evidence that neurotensin participates in the central regulation of the preovulatory surge of luteinizing hormone in the rat, Endocrinology, 124 (1989) 783-788.
2. 2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat, Mol. Brain Res., 11 (1991) 161-166.
3. [3] Azzi, M., Gully, D., Heaulme, M., Bérod, A., Pélaprat, D., Kitabgi, P., Boigegrain, R., Maffrand, J.P., LeFur, G. and Rostène, W., Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists, Eur. J. Pharmacol., 255 (1994) 167-174.
4. [4] Azzi, M., Nicot, A., Gully, D., Kitabgi, P., Bérod, A. and Rostène, W., Increase in neurotensin receptor expression in rat brain induced by chronic treatment with the nonpeptide neurotensin receptor antagonist, SR 48692, Neurosci. Lett., 172 (1994) 97-100.
5. 3[H]SR 48692, in the guinea pig brain, J. Pharmacol. Exp. Ther., 273 (1995) 1450-1458.
6. [6] Boudin, H., Gruaz-Guyon, A., Faure, M.P., Forgez, P., Lhiaubet, A.M., Dennis, M., Beaudet, A., Rostène, W. and Pélaprat, D., Immunological recognition of different forms of the neurotensin receptor in transfected cells and rat brain, Biochem. J. , 305 (1995) 277-283.
7. [7] Boudin, H., Pélaprat, D., Rostène, W. and Beaudet, A., Cellular distribution of the neurotensin receptor in rat brain: immunohistochemical study using an antipeptide antibody, J. Comp. Neurol., (1996) in press.
8. 2-adrenergic receptor delays onset of agonist-promoted desensitization, Nature, 333 (1988) 370-373.
9. 3H-dopamine release in rat striatal slices and mesencephalic cultures, Eur. J. Pharmacol., 253 (1994) 289-291.
10. 3H]-(±)-L-364,718: A new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors, Mol. Pharmacol., 30 (1986) 212-217.
11. 8]neurotensin(8-13), J. Pharmacol. Exp. Ther., 264 (1993) 1-5.
12. [12] Dubuc, I., Costentin, J., Terranova, J.P., Barnouin, M.C., Soubrié, P., Le Fur, G., Rostène, W. and Kitabgi, P., The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes, Br. J. Pharmacol., 112 (1994) 352-354.
13. [13] Dussaillant, M., Sarrieau, A., Gozes, I., Bérod, A. and Rostène W., Distribution of cells expressing vasoactive intestinal peptide/peptide histidine isoleucine-amide precursor messenger RNA in the rat brain, Neuroscience, 50 (1992) 519-530.
14. [14] Emson, P.C., Goedert, M., Horsfield, P., Rioux, F. and St Pierre, S., The regional distribution and chromatographic characterisation of neurotensin-like immunoreactivity in rat central nervous system, J. Neurochem., 38 (1982) 992-999.
15. [15] Faure, M.P., Alonso, A., Nouel, D., Gaudriault, G., Dennis, M., Vincent, J.P. and Beaudet, A., Somatodendritic internalization and perinuclear targeting of neurotensin in the mammalian brain, J. Neurosci., 15 (1995) 4140-4147.
16. [16] Febvret, A., Berger, B., Gaspar, P. and Verney, C., Further indication that distinct dopaminergic subsets project to the rat cerebral cortex: lack of colocalization with neurotensin in the superficial dopaminergic fields of the anterior cingulate, motor, retrosplenial and visual cortices, Brain Res., 547 (1991) 37-52.
17. [17] Goldstein, A., Aronow, L. and Kalman, S.M., Consequences of drug-receptor interactions: analysis of the graded dose-response relationship. In Principles of Drug Action: the Basis of Pharmacology, 2nd edn., Wiley, New York, 1974, pp. 82-111.
18. 2 dopamine receptor protein independently of RNA levels in mice, Life Sci., 48 (1991) 1015-1022.
19. [19] Gully, D., Canton, M., Boigegrain, R., Jeanjean, F., Molimard, J.C., Poncelet, M., Gueudet, C., Heaulme, M., Leyris, R., Brouard, A., Pélaprat, D., Labbé-Jullié, C., Mazella, J., Soubrié, P., Maffrand, J.P., Rostène, W., Kitabgi, P. and Le Fur, G., Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of neurotensin receptor, Proc. Natl. Acad. Sci. USA, 90 (1993) 65-69.
20. [20] Jennes, L., Stumpf, W.E. and Kalivas, P.W., Neurotensin: topographical distribution in rat brain by immunohistochemistry, J. Comp. Neurol., 210 (1982) 211-224.
21. [21] Hughes, J., Boden, P., Costall, B., Doheney, A., Kelly, E., Horwell, E.C., Hunter, J.C., Pinnock, R.D. and Woodruff, G.N., Development of a class of selective cholecystokinin Type B receptor antagonists having potent anxiolytic activity, Proc. Natl. Acad. Sci. USA, 87 (1990) 6728-6732.
22. [22] Kasckow, J. and Nemeroff, C.B., The neurobiology of neurotensin: focus on neurotensin-dopamine interactions, Regul. Peptides, 36 (1991) 153-164.
23. [23] Kitabgi, P., Rostène, W., Dussaillant, M., Schotte, A., Laduron, P.M. and Vincent, J.P., Two populations of neurotensin binding sites in murine brain: discrimination by antihistamine levocabastine reveals markedly different radioautographic distribution, Eur. J. Pharmacol., 140 (1987) 285-293.
24. [24] Kitabgi, P., Neurotensin modulates dopamine transmission at several levels along dopaminergic pathways, Neurochem. Int., 14 (1989) 111-119.
25. 3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: Characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor, Mol. Pharmacol., 47 (1995) 1050-1056.
26. [26] Lapchak, P.A., Araujo, D.M., Quirion, R. and Beaudet, A., Neurotensin regulation of endogenous acetylcholine release from rat cerebral cortex: effect of quinolinic acid lesions of the basal forebrain, J. Neurochem., 55 (1990) 1397-1403.
27. [27] Lapchak, P.A., Araujo, D.M., Quirion, R. and Beaudet, A., Neurotensin regulation of endogenous acetylcholine release from rat striatal slices is independent of dopaminergic tone, J. Neurochem., 56 (1991) 651-657.
28. [28] Mazelta, J., Leonard, K., Chabry, J., Kitabgi, P., Vincent, J.P. and Beaudet, A., Binding and internalization of iodinated neurotensin in neuronal cultures from embryonic mouse brain, Brain Res., 564 (1991) 249-255.
29. [29] McKinney, M. and Robbins, M., Chronic atropine administration up-regulates rat cortical muscarinic m1 receptor mRNA molecules: assessment with the RT/PCR, Mol. Brain Res., 12 (1992) 39-45.
30. [30] Miyamoto-Lee, Y., Shiosaka, S. and Tohyama, M., Purification and characterization of neurotensin receptor from rat brain with special reference to comparison between newborn and adult age rats, Peptides, 12 (1991) 1001-1006.
31. 3neurotensin, Neuroscience, 22 (1987) 525-536.
32. [32] Munson, P.J. and Rodbard, D., LIGAND: A versatile computerized approach for characterization of ligand-binding systems, Anal. Biochem., 107 (1980) 220-239.
33. [33] Nemeroff, C.B. and Cain, S.T., Neurotensin-dopamine interaction in the central nervous system, Trends Pharmacol. Sci., 6 (1985) 201-205.
34. [34] Nicot, A., Bérod, A., Gully, D., Rowe, W., Quirion, R., de Kloet, E.R. and Rostène, W., Blockade of neurotensin binding in the rat hypothalamus and of the central action of neurotensin on the hypothalamo-pituitary-adrenal axis with non-peptide receptor antagonists, Neuroendocrinology, 59 (1994), 572-578.
35. [35] Nicot, A., Rostène, W. and Bérod, A., Neurotensin receptor expression in the rat forebrain and midbrain: a combined analysis by in situ hybridization and receptor autoradiography study, J. Comp. Neurol., 341 (1994), 407-419.
36. [36] Oury-Donat, F., Thurneyssen, O., Gonalons, N., Forgez, P., Gully, D., Le Fur, G. and Soubrié, P., Characterization of the effect of SR 48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non-neuronal cells, Br. J. Pharmacol., 119 (1995) 1899-1905.
37. [37] Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, Academic Press, North Ryde, Australia, 1986.
38. [38] Poncelet, M., Armone, M., Heaulme, M., Gonalons, N., Gueudet, C., Santucci, V., Thurneyssen, O., Keane, P., Gully, D., Le Fur, G. and Soubrié, P., Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist, Naunyn-Schmiedeberg's Arch. Pharmacol., 348 (1993) 102-107.
39. [39] Poncelet, M., Gueudet, C., Gully, D., Soubrié, P. and Le Fur, G., Turning behaviour induced by intrastriatal injection of neurotensin in mice: sensitivity to non-peptide neurotensin antagonists, Naunyn-Schmiedeberg's Arch. Pharmacol., 349 (1994) 57-60.
40. 2 receptors in mouse brain, Mol. Pharmacol., 43 (1992) 84-89.
41. [41] Rosenbaum, J.S., Holford, N.H.G. and Sadée, W., Opiate receptor binding-effect relationship: Sufentanil and Ethorphine produce analgesia at the μ-site with low fractional receptor occupancy, Brain Res., 291 (1984) 317-324.
42. [42] Rostène, W., Brouard, A., Dana, C., Masuo, Y., Agid, F., Vial, M., Lhiaubet, A.M. and Pélaprat, D., Interaction between neurotensin and dopamine in the brain: Morphofonctional and clinical evidence, Ann. NY Acad. Sci., 668 (1992) 217-231.
43. [43] Sadoul, J.L., Mazella, J., Amar, S., Kitabgi, P. and Vincent J.P., Preparation of neurotensin selectively iodinated on the tyrosine 3 residue. Biological activity and binding properties on mammalian neurotensin receptors, Biochem. Biophys. Res. Commun., 120 (1984) 812-819.
44. [44] Scarcériaux, V., Pélaprat, D., Lhiaubet, A.M., Schimpff, R.M., Tramu, G. and Rostène, W., Developmental pattern of neurotensin content in rat hypothalamic neurons cultured in serum-free medium: comparison with in vivo data, Dev. Brain Res., 81 (1994) 128-130.
45. 4 receptors by 2-fold in rats, Eur. J. Pharmacol., 289 (1995) 67-72.
46. 3H-neurotensin binding site in rat brain, Naunyn-Schmiederberg's Arch. Pharmacol., 333 (1986) 400-405.
47. [47] Steinberg, R., Brun, P., Fournier, M., Souilhac, J., Rodier, D., Mons, G., Terranova, J. P., Le Fur, G. and Soubrié, P., SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission, Neuroscience, 59 (1994) 921-929.
48. [48] Steinberg, R., Rodier, D., Mons, G., Gully, D., Le Fur, G. and Soubrié, P., SR 48692-sensitive neurotensin receptors modulate acetylcholine release in the rat striatum, Neuropeptides, 29 (1995) 27-31.
49. [49] Talkad, V.D., Fortune, K.P., Pollo, D.A., Shah, G.N., Wank, S.A. and Gardner, J.D., Direct demonstration of three different states of the pancreatic cholecystokinin receptor, Proc. Natl. Acad. Sci. USA, 91 (1994) 1868-1872.
50. [50] Tanaka, K., Masu, M. and Nakanishi, S., Structure and functional expression of the cloned rat neurotensin receptor, Neuron, 4 (1990) 847-854.
51. 3-muscarinic receptors revealed by immunoprecipitation, J. Biol. Chem., 268 (1993) 9817-9823.
52. [52] Uhl, G.R. and Snyder, S., Regional and subcellular distribution of brain neurotensin, Life Sci., 19 (1977) 1827-1832.
53. [53] Uhl, G.R., Goodman, R. and Snyder, S., Neurotensin-containing cell bodies, fibers and nerve terminals in the brain stem of the rat: immunohistochemical mapping, Brain Res., 167 (1979) 77-91.
54. [54] Vanisberg, M.A., Maloteaux, J.M., Octave, J.N. and Laduron, P.M., Rapid agonist-induced decrease of neurotensin receptors from the cell surface in rat cultured neurons, Biochem. Pharmacol., 42 (1991) 2265-2274.
55. [55] Vita, N., Laurent, P., Lefort, S., Chalon, P., Dumont, X., Kaghad, M., Gully, D., Le Fur, G., Ferrera, P. and Caput, D., Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor, FEBS Lett., 317 (1993) 139-142.
56. [56] Vijayan, E., Carraway, R., Leeman, S.E. and McCann, S.M., Physiological significance of neurotensin in pituitary glycoprotein hormone release as revealed by in vivo and in vitro studies with neurotensin antiserum, Neuroendocrinology, 60 (1994) 157-164.
57. [57] Waelbroeck, M., Robberecht, P., Chatelain, P. and Christophe, J., Rat cardiac muscarinic receptors. I. Effects of guanine nucleotides on high-and low-affinity binding sites, Mol. Pharmacol., 21 (1982) 581-588.
58. [58] Watson, M., Isackson, P.J., Makker, M., Yamada, M.S., Yamada, M., Cusack, B. and Richelson, E., Identification of a polymorphism in the human neurotensin receptor gene, Mayo Clin. Proc., 68 (1993) 1043-1048.
59. [59] Yamada, M., Bolden-Watson, C., Watson, M.A., Cho, T., Coleman, N.J., Yamada, M. and Richelson, E., Regulation of neurotensin receptor mRNA expression by the receptor antagonist SR 48692 in the rat midbrain dopaminergic neurons, Mol. Brain Res., 334 (1995) 343-346.